Yahoo · Sep 2, 2026
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
The latest trading day saw Abbott (ABT) settling at $110.47, representing a +1.41% change from its previous close.
AB
NASDAQ · ABT
Abbott Laboratories
Healthcare · Medical - Devices
$110.47
Up+$1.56 (+1.43%)
Updated Sep 3, 2026, 5:28 AM
SID Score
7.3/10
Composite research score
Smart Money
51/100
Neutral
- Market cap
- 202.45B
- P/E ratio
- 31.15
- Dividend yield
- 2.14%
- 52-week range
- $81.97 – $129.64
- Volume
- 8.46M
- Avg. volume
- 8.88M
Price performance
ABT price history
1M range · 21 trading sessions · Daily adjusted prices
ABT closed at $110.47 after 21 trading sessions, up 4.50% for the selected period.
- Last close
- $110.47
- Period change
- +4.50%
- Period low
- $105.71
- Period high
- $116.67
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $109.32 | $112.20 | $109.00 | $110.47 | 8.46M |
| Sep 1, 2026 | $112.25 | $113.91 | $108.68 | $108.93 | 7.23M |
| Aug 31, 2026 | $111.54 | $111.64 | $109.54 | $110.36 | 10.69M |
| Aug 28, 2026 | $111.60 | $112.75 | $111.11 | $112.47 | 7.55M |
| Aug 27, 2026 | $112.75 | $113.45 | $111.29 | $111.59 | 8.36M |
| Aug 26, 2026 | $115.40 | $116.715 | $114.005 | $114.10 | 6.96M |
| Aug 25, 2026 | $115.83 | $116.61 | $115.035 | $116.13 | 7.5M |
| Aug 24, 2026 | $116.28 | $117.34 | $115.82 | $116.67 | 5.92M |
| Aug 21, 2026 | $114.02 | $116.66 | $113.4501 | $116.64 | 9.93M |
| Aug 20, 2026 | $114.00 | $115.23 | $113.99 | $114.14 | 5.79M |
| Aug 19, 2026 | $113.23 | $115.67 | $112.91 | $114.43 | 7.4M |
| Aug 18, 2026 | $112.45 | $113.63 | $111.745 | $112.68 | 9.78M |
| Aug 17, 2026 | $110.04 | $111.41 | $109.35 | $110.37 | 11.46M |
| Aug 14, 2026 | $111.49 | $111.97 | $110.79 | $111.25 | 5.58M |
| Aug 13, 2026 | $112.47 | $112.47 | $110.46 | $111.27 | 5.52M |
| Aug 12, 2026 | $108.05 | $111.28 | $107.50 | $110.91 | 6.61M |
| Aug 11, 2026 | $108.62 | $110.185 | $107.921 | $109.72 | 6.74M |
| Aug 10, 2026 | $107.41 | $109.09 | $107.36 | $108.62 | 5.6M |
| Aug 7, 2026 | $107.03 | $107.97 | $106.01 | $107.81 | 6.61M |
| Aug 6, 2026 | $107.185 | $107.99 | $105.56 | $107.96 | 9.8M |
| Aug 5, 2026 | $106.71 | $106.76 | $104.20 | $105.71 | 9.31M |
Latest ABT news
The latest Smart Investors Daily articles mentioning ABT.
Stock researchCompany · Overview
ABT research
Overview
Company profile and research snapshot.
Company profile
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $151.40
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | TD Cowen | Buy | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Jul 28, 2026 | UBS | Buy | — |
| Jul 17, 2026 | TD Cowen | Buy | — |
| Jul 17, 2026 | RBC Capital | Outperform | — |
News briefing
Generated Sep 2, 2026, 9:00 PM
Why Is ABT Up 1.43% Today?
Abbott Laboratories gained 1.43% today in a modest rally that appears driven by positive momentum in the broader healthcare sector rather than company-specific catalysts. The stock's performance reflects strength among diversified healthcare players, particularly following peer Medtronic's beat-and-raise guidance this earnings season.
Bottom line: Abbott's 1.43% gain appears driven by positive sector momentum from Medtronic's strong quarter and renewed healthcare investor appetite, rather than company-specific catalysts. While the absence of negative news is supportive, investors should watch for ABT's next earnings report and conference presentations to validate current momentum with fundamental improvements. The stock's gains remain somewhat vulnerable without concrete operational or strategic announcements to support higher valuations.
Yahoo · Sep 2, 2026
Median Technologies Announces Formation of Strategic Review Committee and R&D Committee to Unlock Intrinsic Value and Accelerate Its eyonis® Pan-Cancer Strategy
SOPHIA ANTIPOLIS, France, September 02, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of AI-powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that its Board of Directors has formed a Strategic Review Committee (the "SRC")
Yahoo · Sep 2, 2026
3 Reasons to Sell PACB and 1 Stock to Buy Instead
Shareholders of PacBio would probably like to forget the past six months even happened. The stock dropped 20.5% and now trades at $1.29. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Yahoo · Sep 2, 2026
Why Is Inspire (INSP) Down 4.1% Since Last Earnings Report?
Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AI research layers
Interpretive context generated from the platform’s current data sources.
Abbott Laboratories Stock Performance
Abbott Laboratories shares closed at $108.97, reflecting a modest daily gain of 0.47% per SID market data. Over the trailing one-month period, ABT has risen $1.69, while the three-month return stands at a more substantial $25.25, indicating meaningful recovery momentum. However, the stock remains down 13.13% over the past twelve months, underperforming the broader healthcare sector. From a technical perspective, ABT trades above both its 50-day moving average of $103.31 and its 200-day moving average of $103.83, according to Massive/Polygon data, suggesting the stock has recently reclaimed key support levels. The 14-day relative strength index reads 44.4, positioning ABT in neutral territory without overbought or oversold signals. Average daily volume stands at approximately 8.88 million shares. The stock carries a beta of 0.751, indicating lower volatility relative to the broader market, consistent with its defensive healthcare positioning.
Abbott Laboratories Valuation Analysis
Abbott Laboratories carries a market capitalization of approximately $202.5 billion, positioning it among the largest healthcare companies globally, per SID market data. The stock trades at a price-to-earnings ratio of 31.15, which sits above the healthcare sector median, reflecting a premium valuation that investors have historically assigned to Abbott's diversified medical device and diagnostics portfolio. The price-to-book ratio stands at 3.90, according to SEC filings, indicating the market values the company at nearly four times its book equity. Notably, the PEG ratio registers at negative 0.58, suggesting analysts may be modeling earnings growth deceleration in certain segments. Abbott currently offers a dividend yield of 2.06%, providing income-oriented investors with a steady return component. The combination of an elevated P/E multiple with a negative PEG ratio warrants close monitoring of forward earnings trajectory to determine whether the current premium valuation is supported by fundamental growth drivers.
Smart Money Activity for ABT
Abbott Laboratories registers a smart money composite score of 51 out of 100, signaling a neutral stance among sophisticated market participants, per SID market data. The institutional sub-score reaches a perfect 25 out of 25, indicating strong conviction and sustained positioning from large fund managers, according to 13F institutional filings. In contrast, the insider trading sub-score sits at 9.7 out of 25, reflecting relatively muted directional signals from corporate executives. SEC Form 4 filings reveal 14 insider transactions over the past 90 days, evenly split between seven purchases and seven sales, producing no discernible net directional bias. The dark pool activity sub-score of 8.5 out of 25 suggests below-average institutional block trading interest at current price levels. Congressional trading activity scores 7.6 out of 25, indicating limited recent legislative member transactions in ABT shares. The divergence between maximum institutional conviction and tepid insider activity creates a mixed signal profile that reflects the stock's current transitional positioning between recovery and sustained momentum.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has demonstrated a consistent pattern of meeting or exceeding consensus expectations across recent quarters, according to company earnings reports. In the most recently reported quarter, Abbott posted earnings per share of $1.31, surpassing the analyst estimate of $1.28 by $0.03, representing a positive surprise of approximately 2.3%. The prior quarter likewise delivered a modest beat, with actual EPS of $1.15 versus the $1.14 consensus estimate. In the January 2026 reporting period, Abbott matched analyst expectations exactly at $1.50 per share, showing no surprise. The upcoming quarter carries a consensus estimate of $1.15 per share, per analyst estimates, with results pending. The sequential EPS trajectory from $1.50 to $1.15 to $1.31 reflects some quarterly variability, though the consistent ability to meet or exceed estimates suggests disciplined guidance management. Investors will monitor whether Abbott can sustain its beat cadence in the next reporting cycle.
Wall Street Analyst Ratings for ABT
Wall Street coverage of Abbott Laboratories reflects a decidedly bullish consensus, with recent analyst actions uniformly maintaining or upgrading ratings, per SID consensus data. On August 25, 2026, TD Cowen reiterated its Buy rating, reinforcing confidence in the company's growth trajectory. Wolfe Research issued the most notable action on August 13, upgrading ABT to Outperform from Peer Perform, signaling a constructive shift in the firm's thesis. UBS maintained its Buy rating on July 28, while both TD Cowen and RBC Capital reiterated Buy and Outperform ratings respectively on July 17 following the earnings release, according to Wall Street analyst reports. Across the five most recent ratings, no analyst has issued a Hold or Sell recommendation, suggesting broad agreement on Abbott's fundamental strength. The Wolfe Research upgrade is particularly significant as it represents new buying conviction rather than a maintenance of existing positioning, potentially catalyzing incremental institutional interest at current valuation levels near $108.97.
